<DOC>
	<DOCNO>NCT00936234</DOCNO>
	<brief_summary>SDF-1 , important cytokine neovascularisation cleave ( dipeptidyl peptidase IV ) DPPIV . The aim study assess effect dipeptidyl peptidase IV inhibitor vildagliptin ( GalvusÂ® ) endothelial function well number functional activity progenitor cell patient document diabetes mellitus .</brief_summary>
	<brief_title>Functional Improvement Progenitor Cells Endothelial Function Vildagliptin Diabetes Mellitus ( FINNjA-DM ) .</brief_title>
	<detailed_description>The peptidase CD26 ( DPPIV/dipeptidyl peptidase IV ) remove dipeptides amino terminus protein thereby inactivate cleaved protein . It show , CD26 cleave SDF-1 non-mitogenic molecule . Inhibition deletion CD26 lead increase home hematopoietic progenitor cell bone marrow transplantation increase invasion capacity cell { Campbell et al . 2008 ; Christopherson et al . 2004 } . The cytokine SDF-1 release response hypoxia , crucial progenitor cell home recruitment cell neovascularisation . Invasion capacity closely related cytokine SDF-1 SDF-1 receptor CXCR4 { Ceradini et al . 2004 } . The vivo neovascularisation capacity progenitor cell closely correlate functional capacity SDF-1 induce invasion colony-forming capacity { Heeschen et al . 2004 ; Britten et al . 2003 ; Assmus et al . 2007 } . Therefore , aim study assess effect dipeptidyl peptidase IV inhibitor vildagliptin endothelial function well number functional activity progenitor cell patient document diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients diabetes mellitus type 2 stable medication HbA1c 7 % 10 % age 18 80 year sign informed consent Atrial fibrillation ( plethysmographic recording obtain sinusrhythm ) CAD reduce leave ventricular ejection fraction ( LVEF &lt; 45 % ) Pregnancy , chronic acute infection , fever Diabetes mellitus type 1 Newly diagnose diabetes , uncontrolled diabetes Neoplasm Known allergy study drug Severe liver/kidney disease HIV , Hepatitis Participation study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>CAD</keyword>
	<keyword>diabetes</keyword>
	<keyword>SDF-1</keyword>
	<keyword>endothelial function</keyword>
</DOC>